The Metabolic Advantage. Studied. Measured. Proven in Research.
Obesity research has entered a new era. Triple-receptor agonists and growth hormone fragments are reshaping how scientists model metabolic dysfunction. Nexora's Weight Management peptides put the most studied metabolic compounds directly in your research pipeline—at uncompromising purity.
2 Compounds Available
All in-stock · Ships worldwide
AOD-9604
NXR-AOD9604-5MGAOD-9604 is a synthetic analogue of the human growth hormone studied for its metabolic effects in research settings.
Retatrutide
NXR-RETAT-10MGRetatrutide is a triple agonist peptide studied for its effects on metabolic pathways in preclinical research.
The Science Behind Weight Management
Lipolysis Research
AOD-9604 is a 15-amino-acid fragment of the C-terminus of human growth hormone—studied specifically for its fat oxidation properties without anabolic interference.
Multi-Receptor Targeting
Retatrutide's GLP-1/GIP/glucagon triple-agonism is driving the most exciting metabolic syndrome research of the decade.
Precision Dosing Models
Formulated for in-vitro and in-vivo research applications requiring high-concentration, high-purity compounds.
Research Notes
Retatrutide (LY3437943) activates receptors for GLP-1, GIP, and glucagon—a mechanism that goes beyond current dual-agonist therapies. AOD-9604 (hGH 176-191) demonstrates lipolytic and antilipogenic activity in animal studies without detectable impact on insulin sensitivity.
Third-Party Tested
Every batch verified by independent HPLC and mass spectrometry before release.
≥99% Purity
Certificate of Analysis included with every order. No compromises.
Research Use Only
Formulated exclusively for licensed researchers and institutions.
Explore Other Research Areas
Ready to Advance Your Research?
Every compound ships with a Certificate of Analysis. Tracked worldwide. Temperature-controlled packaging as standard.